NBDF/LinkedIn
Jul 28, 2025, 15:18
Investigational Therapies for VWD and Glanzmann Thrombasthenia Unveiled at ISTH 2025: 2 Promising Paths Forward
National Bleeding Disorders Foundation (NBDF) shared a post on LinkedIn:
”Big strides in bleeding disorders care! Hemab Therapeutics shares new data on two potential preventive therapies for Glanzmann thrombasthenia and VWD.”
Read the full update here.
Stay updated on the latest news in hematology with Hemostasis Today.
-
Oct 3, 2026, 08:31Víctor S. Rangel: Advanced Endovascular Management in Severe Postpartum CVST
-
Oct 3, 2026, 08:05Are Circadian Rhythms Fueling Thrombotic Risk in Space? – RPTH Journal
-
Oct 3, 2026, 07:43Janez Urevc: Modeling Compression Ultrasound for Internal Jugular Vein Thrombosis in Astronauts
-
Oct 3, 2026, 07:20Adam Wufsus: Novo Nordisk Seeks Medical Liaison for Sickle Cell Disease
-
Oct 3, 2026, 07:16Álvaro Dubois-Silva: Rethinking the Obesity Paradox in Cancer-Associated VTE
-
Oct 3, 2026, 07:09Lori Bryngelson Taylor: Expert Consensus Guidelines Flag Hypophosphatemia Risks With Injectafer
-
Oct 3, 2026, 06:40Aayush Bist: Study Reveals Distinct Social Patterns in Anemia, Excess Adiposity, and High Blood Pressure Among Women in Nepal
-
Oct 3, 2026, 06:39Ahmed Bennis: Understanding the Diagnosis, Risk, and Management of ARN
-
Oct 3, 2026, 06:11Ana Cespedes: Maternal Anemia in Pregnancy Linked to Differences in Infant Brain Structure